Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 171

1.

Inter-rater reliability and validity of good pharmacy practices measures in inspection of public sector health facility pharmacies in Uganda.

Sekayombya B, Nahamya D, Garabedian L, Seru M, Trap B.

J Pharm Policy Pract. 2019 Jan 22;12:2. doi: 10.1186/s40545-018-0161-y. eCollection 2019.

2.

Use of generic medicines in Latvia: awareness, opinions and experiences of the population.

Salmane Kulikovska I, Poplavska E, Ceha M, Mezinska S.

J Pharm Policy Pract. 2019 Jan 6;12:1. doi: 10.1186/s40545-018-0159-5. eCollection 2019.

3.

To sell or not to sell; the differences between regulatory and community demands regarding access to antibiotics in rural Ghana.

Afari-Asiedu S, Kinsman J, Boamah-Kaali E, Abdulai MA, Gyapong M, Sankoh O, Hulscher M, Asante KP, Wertheim H.

J Pharm Policy Pract. 2018 Dec 14;11:30. doi: 10.1186/s40545-018-0158-6. eCollection 2018.

4.

Patent challenges in the procurement and supply of generic new essential medicines and lessons from HIV in the southern African development community (SADC) region.

't Hoen EFM, Kujinga T, Boulet P.

J Pharm Policy Pract. 2018 Dec 4;11:31. doi: 10.1186/s40545-018-0157-7. eCollection 2018. Review.

5.

Generic prescription drug price increases: which products will be affected by proposed anti-gouging legislation?

Conti RM, Nguyen KH, Rosenthal MB.

J Pharm Policy Pract. 2018 Nov 21;11:29. doi: 10.1186/s40545-018-0156-8. eCollection 2018.

6.

Assessment of knowledge, attitude and practice towards disposal of unused and expired pharmaceuticals among community in Harar city, Eastern Ethiopia.

Ayele Y, Mamu M.

J Pharm Policy Pract. 2018 Nov 15;11:27. doi: 10.1186/s40545-018-0155-9. eCollection 2018.

7.

Prescription drug coverage in Canada: a review of the economic, policy and political considerations for universal pharmacare.

Brandt J, Shearer B, Morgan SG.

J Pharm Policy Pract. 2018 Nov 7;11:28. doi: 10.1186/s40545-018-0154-x. eCollection 2018. Review.

8.

Access to innovative cancer medicines in a middle-income country - the case of Mexico.

Moye-Holz D, Soria Saucedo R, van Dijk JP, Reijneveld SA, Hogerzeil HV.

J Pharm Policy Pract. 2018 Oct 24;11:25. doi: 10.1186/s40545-018-0153-y. eCollection 2018.

9.
10.

Pharmaceutical system strengthening in Uganda: implementing a holistic, evidence-informed, long-term strategy.

Oteba M, Wagner AK, Seru M, Embrey M, Trap B.

J Pharm Policy Pract. 2018 Oct 15;11:23. doi: 10.1186/s40545-018-0150-1. eCollection 2018.

11.

Trade agreements and drug access: assessment of the impact of the 2009 Peruvian new drug policy on anti-infectives registration and availability.

Araujo L, Montagne M.

J Pharm Policy Pract. 2018 Oct 10;11:24. doi: 10.1186/s40545-018-0151-0. eCollection 2018.

12.

Country ownership and sustainability of Nigeria's HIV/AIDS Supply Chain System: qualitative perceptions of progress, challenges and prospects.

Itiola AJ, Agu KA.

J Pharm Policy Pract. 2018 Sep 10;11:21. doi: 10.1186/s40545-018-0148-8. eCollection 2018.

13.

An analysis of pharmacy workforce capacity in Nigeria.

Ekpenyong A, Udoh A, Kpokiri E, Bates I.

J Pharm Policy Pract. 2018 Sep 3;11:20. doi: 10.1186/s40545-018-0147-9. eCollection 2018.

14.

Perceptions of the Malaysian general public on community pharmacy-based weight management services.

Verma RK, Paraidathathu T, Taha NA, Chong WW.

J Pharm Policy Pract. 2018 Aug 8;11:17. doi: 10.1186/s40545-018-0146-x. eCollection 2018.

15.

NPS MedicineWise: 20 years of change.

Weekes LM, Blogg S, Jackson S, Hosking K.

J Pharm Policy Pract. 2018 Aug 1;11:19. doi: 10.1186/s40545-018-0145-y. eCollection 2018.

16.

A qualitative exploration of knowledge, attitudes and practices of hospital pharmacists towards adverse drug reaction reporting system in Lahore, Pakistan.

Hussain R, Hassali MA, Hashmi F, Farooqui M.

J Pharm Policy Pract. 2018 Jul 19;11:16. doi: 10.1186/s40545-018-0143-0. eCollection 2018.

17.

Comment on Hernandez-Vasquez et al., a bibliometric analysis of the global research on biosimilars.

Cohen HP.

J Pharm Policy Pract. 2018 Jul 16;11:18. doi: 10.1186/s40545-018-0144-z. eCollection 2018.

18.

Article 2: Longitudinal study assessing the one-year effects of supervision performance assessment and recognition strategy (SPARS) to improve medicines management in Uganda health facilities.

Trap B, Musoke R, Kirunda A, Oteba MO, Embrey M, Ross-Degnan D.

J Pharm Policy Pract. 2018 Jul 5;11:15. doi: 10.1186/s40545-018-0142-1. eCollection 2018.

19.

Regulatory requirements for the registration of generic medicines and format of drug dossiers: procedures in Sri Lanka in comparison with selected regulatory authorities.

Thambavita D, Galappatthy P, Jayakody RL.

J Pharm Policy Pract. 2018 Jun 21;11:14. doi: 10.1186/s40545-018-0141-2. eCollection 2018.

20.

Assessment of primary labeling of medicines manufactured by Nepalese pharmaceutical industries.

Poudel RS, Shrestha S, Thapa S, Poudel BK, Chhetri M.

J Pharm Policy Pract. 2018 Jun 7;11:13. doi: 10.1186/s40545-018-0139-9. eCollection 2018.

Supplemental Content

Loading ...
Support Center